Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A. (NWPHF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nwphf · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Newron Pharmaceuticals S.p.A. (NWPHF) measures how much investors pay for each dollar of the company's trailing earnings. NWPHF's current PE ratio of N/A is calculated by dividing its stock price of $20.00 by its TTM earnings per share of -$0.66.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Newron Pharmaceuticals S.p.A.You NWPHF | $416M | N/A | — | -$0.66 |
 Adocia S.A. ADOCY | $170M | N/A | — | -$0.81 |
 AnGes, Inc. AMGXF | $143M | N/A | — | -$14.45 |
 NIOX Group Plc CSSPF | $274M | 40.40x | +41.2% | $0.02 |
 Dialogue Health Technologies Inc. DLHTF | $255M | N/A | — | -$0.39 |
 Faron Pharmaceuticals Oy FPHAF | $210M | N/A | — | -$0.00 |
 Guerbet S.A. GUERF | $281M | 16.84x | -41.2% | $1.28 |
Industry Average 2 peers with valid PE | — | 28.62x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | 10.81x | $0.85 | — | |
2023-12-31 FY2023 | — | $-0.91 | — | |
2022-12-31 FY2022 | — | $-0.98 | — | |
2021-12-31 FY2021 | — | $-0.84 | — | |
2020-12-31 FY2020 | — | $-1.18 | — | |
2019-12-31 FY2019 | — | $-1.13 | — | |
2018-12-31 FY2018 | — | $-0.84 | — | |
2017-12-31 FY2017 | — | $-0.32 | — | |
2016-12-31 FY2016 | — | $-1.04 | — | |
2015-12-31 FY2015 | — | $-1.66 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Newron Pharmaceuticals S.p.A. (NWPHF) measures how much investors pay for each dollar of the company's trailing earnings. NWPHF's current PE ratio of N/A is calculated by dividing its stock price of $20.00 by its TTM earnings per share of -$0.66.
Frequently asked questions
NWPHF pe ratio · 6 questionsNWPHF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $20.00 and TTM EPS of -$0.66. Data sourced from Financial Modeling Prep via NWPHF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Newron Pharmaceuticals S.p.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09